The management of the patient with acromegaly and headache: A still open clinical challenge

Journal of Endocrinological Investigation

Volumn 31, Issue 10, 2008, Pages 919-924

  Giustina, A ^a,g   Gola, M ^a   Colao, A ^b   De Marinis, L ^c   Losa, M ^d   Sicolo, N ^e   Ghigo, E ^f  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g Montichiari Hospital   (Italy)

Author keywords

Acromegaly; GH; Headache; Octreotide; Somatostatin analogs

Indexed keywords

BETA CALCITONIN GENE RELATED PEPTIDE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE RECEPTOR; NEUROPEPTIDE Y; OCTREOTIDE; PEGVISOMANT; SOMATOSTATIN DERIVATIVE; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACROMEGALY; ACUTE HEADACHE; ANALGESIC ACTIVITY; ARTICLE; CHRONIC HEADACHE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; GAMMA KNIFE RADIOSURGERY; GENETIC PREDISPOSITION; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HUMAN; HYPOPHYSIS TUMOR; MIGRAINE; NEUROSURGERY; PAIN; PRACTICE GUIDELINE; PREVALENCE; PROTEIN SECRETION; QUALITY OF LIFE; RISK FACTOR; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 58649112612     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346442     Document Type: Article

References (48)

1. Levy MJ, Matharu MS, Meeran K, Powell M, Goadsby PJ. The clinical characteristics of headache in patient with pituitary tumours. Brain 2005, 128: 1921-30.
2. Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders (second edition). Cephalalgia 2004, 24 (Suppl 1): 1-160.
3. Forsyth PA, Posner JB. Headaches in patients with brain tumors - a study of 111 patients. Neurology 1993, 43: 1678-83.
4. Levy MJ, Jäger HR, Powell M, Matharu MS, Meeran K, Goadsby PJ. Pituitary volume and headache: size is not everything. Arch Neurol 2004, 61: 721-5.
5. Millán Guerrero RO, Isaís Cárdenas MA. Headache associated with pituitary adenomas. Headache 1999, 39: 522-3.
6. Greve E, Mai J. Cluster headache-like headaches: a symptomatic feature? A report of three patients with intracranial pathologic findings. Cephalalgia 1988, 8: 79-82.
7. Curto L, Squadrito S, Almoto B, et al. MRI finding of simoultaneous coexistence of growth hormone-secreting pituitary adenoma with intracranial meningioma and carotid artery aneurysms: report a case. Pituitary 2007, 10: 299-305.
8. Gondim JA, Tella OI Jr, Schops M. Intrasellar pressure and tumor volume in pituitary tumor: relation study. Arq Neuropsiquiatr 2006, 64: 971-5.
9. Levy MJ, Jäger HR, Matharu MS, Goadsby PJ. Pitutary tumours and headache: does size matter? Cephalagia 2002, 22: 592.
10. Levy MJ, Matharu M, Goadsby PJ. Chronic headache and pituitary tumors. Curr Pain Headache Rep 2008, 12: 74-8.
11. Pascual J, Freijanes J, Berciano J, Pesquera C. Analgesic effect of octreotide in headache associated with acromegaly is not mediated by opioid mechanisms. Case report. Pain 1991, 47: 341-4.
12. Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res 2007, 68 (Suppl 5): 41-7.
13. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007, 47: 355-63.
14. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. Cancer 2004, 101: 613-9.
15. Ferrante E, Ferraroni M, Castrignanò T, et al. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 2006, 155: 823-9.
16. Karavitaki N, Brufani C, Warner JT, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 2005, 62: 397-409.
17. Colao A, Sarno AD, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003, 148: 325-31.
18. Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A. Cushing's Syndrome. Endocrinol Metab Clin North Am 2008, 37: 135-49, ix.
19. Gordon DA, Hill FM, Ezrin C. Acromegaly: a review of 100 cases. Can Med Assoc J 1962, 87: 1106-9.
20. Lawrence JH, Tobias CA, Linfoot JA, et al. Successful treatment of acromegaly: metabolic and clinical studies in 145 patients. J Clin Endocrinol Metab 1970, 31: 180-98.
21. Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab 2000, 85: 168-74.
22. Colao A, Pivonello R, Spinelli L, et al. A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients. J Endocrinol Invest 2007, 30: 497-506.
23. Dubuisson AS, Backers A, Stevenaert A. Classical pituitary tumour apoplexy: clinical features, managment and outcomes in a series of 24 patients. Clin Neurol Neurosurg 2007, 109: 63-70.
24. Mohr G, Hardy J. Hemorrhage, necrosis, and apoplexy in pituitary adenomas. Surg Neurol 1982, 18: 181-9.
25. Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 2008, 37: 67-99.
26. Yoshino A, Katayama Y, Watanabe T, et al. Apoplexy accompanying pituitary adenoma as a complication of preoperative anterior pituitary function tests. Acta Neurochir (Wien) 2007, 149: 557-65.
27. De Marinis L, Bonadonna S, Bianchi A, Maira G, Giustina A. Primary empty sella. J Clin Endocrinol Metab 2005, 90: 5471-7.
28. Sicolo N, Martini C, Ferla S, et al. Analgesic effect of Sandostatin (SMS 201-995) in acromegaly headache. Minerva Endocrinol 1990, 15: 37-42.
29. Melmed S, Casanueva F, Cavagnini F, et al. Guidelinesfor acromegaly management. J Clin Endocrinol Metab 2002, 87: 4054-8.
30. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
31. Grisoli F, Leclercq T, Jaquet P, et al. Transsphenoidal surgery for acromegaly - long-term results in 100 patients. Sung Neurol 1985, 23: 513-9.
32. Mortini P, Losa M, Barzaghi R, Boari N, Giovanelli M. Results of transsphenoical surgery in a large series of patients with pituitary adenoma. Neurosurgery 2005; 56: 1222-33.
33. Losa M, Gioia L, Picozzi P, et al. The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrin Metab 2008, 93: 2546-52.
34. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005, 153: 737-40.
35. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animal and the human. Endocr Rev 1998, 19: 717-97.
36. Levy MJ, Classey JD, Maneesri S, Meeran K, Powell M, Goadsby PJ. The association between calcitonin gene-related peptide (CGRP), substance P and headache in pituitary tumours. Pituitary 2004, 7: 67-71.
37. Kapicioglu S, Gökce E, Kapicioglu Z, Ovali E. Treatment of migraine attacks with a long-acting somatostatin analogue (octreotide SIMS 201-995). Cephalalgia 1997, 17: 27-30.
38. Williams G, Ball JA, Lawson RA, Joplin GF, Bloom SR, Maskill MR. Analgesic effect of somatostatin analogue (octreotide) in headache associated with pituitary tumours. Br Med J (Clin res Ed) 1987, 295: 247-8.
39. Musolino NR, Marino Júnior R, Bronstein MD. Headache in acromegaly: dramatic improvement with the somatostatin analogue SIMS 201-995. Clin J Pain 1990, 6: 243-5.
40. Levy MJ, Bejon P, Barakat M, Goadsloy PJ, Meeran K. Acromegaly: a unique human headache model. Headache 2003, 43: 794-7.
41. Maffei P, Martini C, Sicolo N. Incomplete analgesic effect of lanreotide in acromegaly. Headache 1997, 37: 299-300.
42. Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A. Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 2006, 29: 86-93.
43. Fedele M, De Martino I, Pivonello R, et al. SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/ prolactin-secreting pituitary adenomas. Clin Cancer Res 2007, 13: 2738-44.
44. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med 2002, 346: 257-70.
45. Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005, 153: 135-41.
46. Muller AF, Kopchick JJ, Flyvbjerg A, van der Lely AJ. Clinical review 166: Growth hormone receptor antagonists. J Clin Endocrinol Metab 2004, 89: 1503-11.
47. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007, 156: 75-82.
48. Webb SM. Quality of life in acromegaly. Neuroendocrinology 2006, 83: 224-9.